SecBot SecBot

SGMT

Sagimet Biosciences Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001400118 Biotech & Drug Discovery
$9.56 −0.02 (−0.21%)
Oct 26 4:00 PM ET · prev $9.58
Market cap
$701.8M
Small cap
Consensus
Buy
89% Buy or better · 19 analysts
Median target
$27.00
+182% · range $7.00–56.00
Next earnings
Nov 12
in 17 days
1 year
+11.2%
from $8.60 · Oct 27
30 days
−3.8%
from $9.94
52-week range
$4.55–11.17
−14% from high · low Mar 30
Avg volume 20D
1.54M
Sep 30 spike 5.45M
Short interest
11.19M
≈15.9% of shares · +9.0%
Days to cover
6.7
at average volume
Insider net
−$4.6M
0 buyers · 5 sellers · 12 mo
New fund stakes
1
Q2 2026 13F · 0 exits
SecBot read MIXED 9 reports · 90 days
Balance 2 bearish · 2 bullish · 1 mixed · 4 neutral oldest → newest, height = score
Avg score ·High conf. 7/9 ·Next Earnings date, Nov 12, 2026
Strongest BEARISH Sagimet Biosciences closed a $115M underwritten offering of 8.75M shares of Series A common stock and…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    5 insiders sold $4.6M.

  • InstitutionsBULLISH

    Q2 2026: 24 added (1 new), 6 trimmed or exited. Largest new: Balyasny Asset Management $28.0M.

  • AnalystsBULLISH

    17 of 19 rate it Buy or better. Median target $27.00 (+182%).

  • Short sellersSTEADY

    Short interest +9.0% to 11.19M shares. 6.7 days to cover, ≈15.9% of shares.

  • TrendDOWNTREND

    4% below its 50-day average.

Who's buying

13F· Q2 2026
1
new positions
0
exits
$28.0M
in new stakes
FundMoveSharesValue
BlackRock, Inc.DOUBLED6,575,788$50.8M
BALYASNY ASSET MANAGEMENT L.P.NEW3,626,113$28.0M
Woodline Partners LPDOUBLED3,000,652$23.2M
VANGUARD CAPITAL MANAGEMENT LLCDOUBLED2,566,272$19.8M
FEDERATED HERMES, INC.DOUBLED2,086,715$16.1M
STATE STREET CORPDOUBLED1,995,092$15.4M
GEODE CAPITAL MANAGEMENT, LLCDOUBLED1,444,019$11.2M
GOLDMAN SACHS GROUP INCDOUBLED759,086$5.9M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

19 analysts
Buy 89% rate it Buy or better
Strong Buy6Buy11Hold1Sell1Strong Sell0
12-month targets · 11 analysts

Price is inside the target range. Median implies +182%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 5, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Oct 2, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Oct 1, 2026Oppenheimer
MAINTAIN
MAINTAINOutperform
Oct 1, 2026Citizens
MAINTAIN
MAINTAINMarket Outperform
Sep 9, 2026Barclays
UPGRADE
UPGRADEOverweight
Sep 9, 2026Cantor Fitzgerald
INITIATE
INITIATEOverweight

Insider ledger

Form 4
$0
bought · 0 insiders
$4.6M
sold · 5 insiders
DateInsiderTypeValue
Aug 14, 2026
Kemble George
Director
EXERCISE$2.1M
Aug 14, 2026
Kemble George
Director
SELL$3.6M
Aug 14, 2026
Kemble George
Director
EXERCISE$155.0K
Aug 11, 2026
Kemble George
Director
EXERCISE$62.0K
Aug 11, 2026
Kemble George
Director
EXERCISE$66.5K
Aug 11, 2026
Kemble George
Director
SELL$201.1K
Jul 20, 2026
Rozek Elizabeth
Chief Legal & Admin. Officer
SELL$81.8K
Jul 20, 2026
Kemble George
Director
SELL$140.5K

Earnings setup

Estimates
Nov 12
reports in 17 days

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Sep 30, 2026
11,189,683
shares short
+9.0%
vs prior settlement
6.7
days to cover
≈15.9%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 22, 2026 SEC
Sagimet Biosciences filed an 8-K with an updated investor presentation on October 22, 2026. The presentation…
8-K — Impact 4/10
Oct 22, 2026 Other
Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne
With first patient dosed in AURORA Phase 3 clinical trial, Sagimet advances denifanstat's U.S. regis
Oct 7, 2026 SEC
Commodore Capital LP filed a Schedule 13G disclosing a 7.6% passive beneficial ownership stake in Sagimet Biosciences…
SC 13G — Impact 4/10
Oct 1, 2026 Press
Sagimet Biosciences closed a $115M underwritten offering of 8.75M shares of Series A common stock and pre-funded…
Impact 6/10
Sep 30, 2026 Press
Sagimet Biosciences priced an underwritten offering of 8,750,010 shares of Series A common stock at $10.00 per share…
Impact 6/10
Sep 30, 2026 SEC
Sagimet announced positive 52-week results from the Phase 3 open-label extension trial (ASC40-304) of denifanstat in…
8-K — Impact 6/10
Aug 14, 2026 Insider
Kemble George acquired via exercise 326,618 shares
Director @ $6.36 ($2.1M)
Aug 14, 2026 Insider
Kemble George sold 350,987 shares
Director @ $10.23 ($3.6M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 12, 2026
Earnings date
SGMT Q3 2026 Earnings Before Market Open — 2026-11-12
Recent
Oct 22, 2026
Press release
Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne
With first patient dosed in AURORA Phase 3 clinical trial, Sagimet advances denifanstat's U.S. registrational program, building on positive Phase 3...
Oct 1, 2026
Activist
Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
FOSTER CITY, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company…
Sep 30, 2026
Activist
Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
FOSTER CITY, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company…
Sep 30, 2026
Press release
Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026
FOSTER CITY, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company…
Aug 25, 2026
FDA
Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026
All clinical trial sites identified and CRO retained

SecBot reports

12 filings · 4 press releases · 3 bullish · 0 bearish · 3 mixed · 6 neutral
All SGMT filing & press-release reports (16)